A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers

ConditionsSmokingTobacco
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-65
SponsorRAI Services Company

About this trial

The overall purpose of this study will be to assess primary combustible cigarette users' abstinence from smoking their usual brand of combustible cigarettes at the end of the study, when provided with an electronic nicotine delivery system (ENDS) power unit (2) and varying levels of access to tobacco-flavored, menthol-flavored, mint, or non-tobacco/non-menthol/non-mint-flavored cartridge-based e-liquids (collectively referred to as the investigational product) within their assigned study arm over a three-month (ninety-day) period.

Eligibility criteria

Qualifiers

Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.

Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent.

All female (assigned at birth) and those who identify as "intersex" or "unknown candidate" participants who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.

Currently smoke at least 5 CC on smoking days in the past 30 days.

Disqualifiers

Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.

Male participants who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or refrain from donating sperm from the signing of the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children.

Female participants who self-report not using adequate methods to prevent pregnancy.

Persons with pacemakers or other embedded electronic medical devices fitted.

Trial design

Treatments tested in this trial

  • P2613422
  • P2611222
  • P2615522
  • P2615122
  • P2615422

Treatment groups

1,280 Participants
are divided into 3 treatment groups

Sponsors and collaborators